Risperidone(continued)
▶Bupropionis predicted to increase the exposure torisperidone.
Adjust dose.oStudy
▶Cinacalcetis predicted to increase the exposure torisperidone.
Adjust dose.oStudy
▶Cobicistatis predicted to increase the exposure torisperidone.
Adjust dose.oStudy
▶Risperidoneis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848→Also seeTABLE 9p. 849
▶Enzalutamideis predicted to decrease the exposure to
risperidone. Adjust dose.oStudy
▶HIV-protease inhibitorsare predicted to increase the exposure
torisperidone. Adjust dose.oStudy→Also seeTABLE 9
p. 849
▶Idelalisibis predicted to increase the exposure torisperidone.
Adjust dose.oStudy
▶Risperidoneis predicted to decrease the effects oflevodopa.
Avoid or adjust dose.rAnecdotal→Also seeTABLE 8p. 848
▶Risperidonepotentially increases the risk of neurotoxicity
when given withlithium.rAnecdotal→Also seeTABLE 9
p. 849
▶Macrolides(clarithromycin)are predicted to increase the
exposure torisperidone. Adjust dose.oStudy→Also see
TABLE 9p. 849
▶Risperidoneincreases the risk of dyskinesias when given with
methylphenidate.rAnecdotal
▶Mitotaneis predicted to decrease the exposure torisperidone.
Adjust dose.oStudy
▶Rifampicinis predicted to decrease the exposure to
risperidone. Adjust dose.oStudy
▶SSRIs(fluoxetine, paroxetine)are predicted to increase the
exposure torisperidone. Adjust dose.oStudy
▶Terbinafineis predicted to increase the exposure to
risperidone. Adjust dose.oStudy
Ritonavir→see HIV-protease inhibitors
Rituximab→see monoclonal antibodies
Rivaroxaban→seeTABLE 3p. 847 (anticoagulant effects)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure torivaroxaban. Avoid.oTheoretical
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to moderately decrease
the exposure torivaroxaban. Avoid unless patient can be
monitored for signs of thrombosis.rStudy
▶Antifungals, azoles(itraconazole, ketoconazole)are predicted to
moderately increase the exposure torivaroxaban. Avoid.
rStudy
▶Enzalutamideis predicted to moderately decrease the
exposure torivaroxaban. Avoid unless patient can be
monitored for signs of thrombosis.rStudy
▶HIV-protease inhibitors(ritonavir)moderately increase the
exposure torivaroxaban. Avoid.rStudy
▶Mitotaneis predicted to moderately decrease the exposure to
rivaroxaban. Avoid unless patient can be monitored for signs
of thrombosis.rStudy
▶Rifampicinis predicted to moderately decrease the exposure
torivaroxaban. Avoid unless patient can be monitored for
signs of thrombosis.rStudy
Rivastigmine→see anticholinesterases, centrally acting
Rizatriptan→seeTABLE 13p. 850 (serotonin syndrome)
▶Beta blockers, non-selective(propranolol)slightly to moderately
increase the exposure torizatriptan. Adjustrizatriptandose
and separate administration by at least 2 hours.oStudy
▶Rizatriptanis predicted to increase the risk of vasoconstriction
when given withergotamine.Ergotamineshould be taken at
least 24 hours before or 6 hours afterrizatriptan.r
Theoretical
▶Moclobemidemoderately increases the exposure torizatriptan.
Avoid.oStudy→Also seeTABLE 13p. 850
▶Monoamine-oxidase A and B inhibitors, irreversibleare
predicted to increase the exposure torizatriptan. Avoid and
for 14 days after stopping the MAOI.rTheoretical→Also
seeTABLE 13p. 850
Rocuronium→see neuromuscular blocking drugs, non-depolarisingRoflumilast
▶Aminophyllineis predicted to slightly increase the exposure to
roflumilast. Avoid.oTheoretical
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
toroflumilast. Avoid.oStudy
▶Combined hormonal contraceptivesare predicted to increase
the exposure toroflumilast.oTheoretical
▶Enzalutamideis predicted to decrease the exposure to
roflumilast. Avoid.oStudy
▶H 2 receptor antagonists(cimetidine)slightly increase the
exposure toroflumilast.oStudy
▶Mitotaneis predicted to decrease the exposure toroflumilast.
Avoid.oStudy
▶Quinolones(ciprofloxacin)are predicted to increase the
exposure toroflumilast.oTheoretical
▶Rifampicinis predicted to decrease the exposure toroflumilast.
Avoid.oStudy
▶SSRIs(fluvoxamine)are predicted to increase the exposure to
roflumilast.oStudy
▶Theophyllineis predicted to slightly increase the exposure to
roflumilast. Avoid.oTheoretical
Rolapitant
▶Rolapitantis predicted to increase the exposure toalkylating
agents(bendamustine). Avoid or monitor.oStudy
▶Rolapitantis predicted to increase the exposure to
anthracyclines(doxorubicin, mitoxantrone). Avoid or monitor.
oStudy
▶Rolapitantis predicted to increase the exposure to
antiarrhythmics(propafenone).rStudy
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to markedly decrease the
exposure torolapitant. Avoid.rStudy
▶Rolapitantis predicted to moderately increase the exposure to
beta blockers, selective(metoprolol).rStudy
▶Bosentanis predicted to decrease the exposure torolapitant.
Avoid.rStudy
▶Rolapitantis predicted to increase the exposure tocolchicine.
oStudy
▶Rolapitantis predicted to increase the exposure todabigatran.
oStudy
▶Rolapitantslightly increases the exposure todigoxin.o
Study
▶Efavirenzis predicted to decrease the exposure torolapitant.
Avoid.rStudy
▶Enzalutamideis predicted to markedly decrease the exposure
torolapitant. Avoid.rStudy
▶Rolapitantis predicted to increase the exposure toirinotecan.
Avoid or monitor.oStudy
▶Rolapitantis predicted to increase the exposure to
methotrexate. Avoid or monitor.oStudy
▶Mitotaneis predicted to markedly decrease the exposure to
rolapitant. Avoid.rStudy
▶Nevirapineis predicted to decrease the exposure torolapitant.
Avoid.rStudy
▶Rolapitantis predicted to increase the exposure topimozide.
rStudy
▶Rifabutinis predicted to decrease the exposure torolapitant.
Avoid.oTheoretical
▶Rifampicinis predicted to markedly decrease the exposure to
rolapitant. Avoid.rStudy
▶St John’s Wortis predicted to decrease the exposure to
rolapitant. Avoid.rStudy
▶Rolapitantis predicted to increase the exposure tostatins
(rosuvastatin). Monitor and adjust dose.rStudy
▶Rolapitantincreases the exposure tosulfasalazine.rStudy
▶Rolapitantis predicted to increase the exposure totamoxifen.
rStudy
▶Rolapitantis predicted to increase the exposure totopotecan.
Avoid or monitor.oStudy
Ropinirole→see dopamine receptor agonists
Ropivacaine→see anaesthetics, local
Rosuvastatin→see statins
Rotavirus vaccine→see live vaccines
Rotigotine→see dopamine receptor agonists986 Risperidone—Rotigotine BNFC 2018 – 2019
Interactions|Appendix 1A1